This is not the most recent version of the article. View current version (16 NOV 2016)

Intervention Review

You have free access to this content

Pharmacological interventions for pruritus in adult palliative care patients

  1. Carola Xander1,*,
  2. Joerg J Meerpohl2,
  3. Daniel Galandi3,
  4. Sabine Buroh4,
  5. Guido Schwarzer5,
  6. Gerd Antes6,
  7. Gerhild Becker7

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 9 JUN 2013

Assessed as up-to-date: 1 APR 2013

DOI: 10.1002/14651858.CD008320.pub2


How to Cite

Xander C, Meerpohl JJ, Galandi D, Buroh S, Schwarzer G, Antes G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008320. DOI: 10.1002/14651858.CD008320.pub2.

Author Information

  1. 1

    German Cochrane Center, Institute of Medical Biometry and Medical Informatics, Freiburg, Germany

  2. 2

    Medical Center - University of Freiburg, Cochrane Germany, Freiburg, Germany

  3. 3

    Ev. Diakoniekrankenhaus Freiburg, Medical Clinic, Freiburg, Germany

  4. 4

    University Medical Center, Library of the Surgical Clinic, Freiburg, Germany

  5. 5

    Medical Center - University of Freiburg, Center for Medical Biometry and Medical Informatics, Freiburg, Germany

  6. 6

    Medical Center – University of Freiburg, Cochrane Germany, Freiburg, Germany

  7. 7

    University Medical Center, Department of Palliative Care, Freiburg, Germany

*Carola Xander, Department of Palliative Care, University Medical Center, Robert Koch Str. 3, Freiburg, 79102, Germany. carola.xander@uniklinik-freiburg.de.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 9 JUN 2013

SEARCH

This is not the most recent version of the article. View current version (16 NOV 2016)

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 1 Pruritus on VAS scale (CKDP/UP and CP).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 2 Pruritus on VAS scale (CKDP/UP vs. CP - subgroup analysis by nature of pruritus).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 3 Pruritus on VAS scale (subgroup analysis by study design).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 4 Pruritus on VAS scale (CKDP/UP and CP) - sensitivity analysis - statistical model.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Nalfurafine versus placebo, Outcome 1 Pruritus on VAS scale (CKDP/UP).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Nalfurafine versus placebo, Outcome 2 Pruritus on VAS scale (CKDPUP) - sensitivity analysis - statistical model.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 1 Ondansetron versus placebo (CKDP/UP and CP) - pruritus on VAS scale.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 2 Ondansetron versus cyproheptadine (CKDP/UP) - pruritus on scale by Duo/Mettang.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 3 Pruritus on VAS scale - subgroup analysis by nature of pruritus (CKDP/UP).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 4 Pruritus on VAS scale - subgroup analysis by nature of pruritus (CP).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 5 Ondansetron (CP and CKDP/UP; different scales).
[Analysis 3.6]
Analysis 3.6. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 6 Pruritus on VAS scale (CKDP/UP and CP) - sensitivity analysis - statistical model.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 7 Pruritus on different scales (CKDP/UP and CP) - sensitivity analysis - statistical model.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Gabapentin versus placebo, Outcome 1 Gabapenten versus placebo (CKDP/UP).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Gabapentin versus placebo, Outcome 2 Gabapentin versus placebo (CKDP/UP) - sensitivity analysis - statistical model.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Rifampin or rifampicin versus placebo or standard medication, Outcome 1 Rifampin/Rifampicin versus placebo/standard medication.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Rifampin or rifampicin versus placebo or standard medication, Outcome 2 Rifampin/Rifampicin versus placebo/standard medication.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Rifampin or rifampicin versus placebo or standard medication, Outcome 3 Rifampin versus placebo/standard medication - sensitivity analysis - statistical model.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Topical capsaicin versus placebo, Outcome 1 Capsaicin versus placebo.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Topical capsaicin versus placebo, Outcome 2 Capsaicin versus placebo - sensitivity analysis - statistical model.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Secondary outcomes: Patient satisfaction, Outcome 1 Patient satisfaction (Paroxetine versus placebo).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Secondary outcomes: Patient satisfaction, Outcome 2 Patient satisfaction (paroxetine versus placebo) - sensitivity analysis - statistical model.